• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction.

作者信息

Washio Takuro, Hissen Sarah L, Takeda Ryosuke, Akins John D, Wakeham Denis J, Brazile Tiffany, Hearon Christopher M, MacNamara James P, Sarma Satyam, Levine Benjamin D, Fadel Paul J, Fu Qi

机构信息

Institute for Exercise and Environmental Medicine at Texas Health Presbyterian Hospital Dallas, 7232 Greenville Ave., Ste. 435, Dallas, TX, 75231-8205, USA.

University of Texas Southwestern Medical Center, Dallas, TX, USA.

出版信息

Clin Auton Res. 2024 Feb;34(1):223-226. doi: 10.1007/s10286-023-01013-0. Epub 2024 Jan 29.

DOI:10.1007/s10286-023-01013-0
PMID:38285071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11031183/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ab/11031183/06e15419e84f/nihms-1985453-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ab/11031183/06e15419e84f/nihms-1985453-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65ab/11031183/06e15419e84f/nihms-1985453-f0001.jpg

相似文献

1
Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction.新型降糖药物降低射血分数保留的心力衰竭患者静息交感神经活性的潜力。
Clin Auton Res. 2024 Feb;34(1):223-226. doi: 10.1007/s10286-023-01013-0. Epub 2024 Jan 29.
2
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.胰高血糖素样肽-1 受体激动剂与心力衰竭：进一步生成证据和优化实践指南的必要性。
Circulation. 2020 Sep 22;142(12):1205-1218. doi: 10.1161/CIRCULATIONAHA.120.045888. Epub 2020 Sep 21.
3
Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.SGLT2 抑制剂与 DPP4 抑制剂和 GLP-1 受体激动剂在射血分数降低和保留的心衰患者中的心血管结局。
Cardiovasc Diabetol. 2023 Mar 10;22(1):54. doi: 10.1186/s12933-023-01784-w.
4
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用：超越 2 型糖尿病。一篇叙述性综述。
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
5
Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.射血分数保留的心力衰竭治疗：联合使用钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂
Eur Heart J. 2024 Aug 9;45(30):2748-2751. doi: 10.1093/eurheartj/ehae414.
6
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.芦格列净对糖尿病合并射血分数保留心力衰竭患者的影响。
J Am Heart Assoc. 2020 Aug 18;9(16):e015103. doi: 10.1161/JAHA.119.015103. Epub 2020 Aug 1.
7
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.欧洲心脏病学会/心力衰竭协会关于新型降糖药物在心力衰竭患者中的作用和安全性的立场文件。
Eur J Heart Fail. 2020 Feb;22(2):196-213. doi: 10.1002/ejhf.1673. Epub 2019 Dec 9.
8
Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide.心力衰竭中的胰高血糖素样肽-1受体激动剂：跨越射血分数鸿沟的STEP研究
J Am Coll Cardiol. 2023 Nov 28;82(22):2097-2100. doi: 10.1016/j.jacc.2023.09.812. Epub 2023 Oct 8.
9
Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.钠-葡萄糖共转运蛋白 2 抑制剂治疗射血分数保留的心力衰竭和伴有或不伴有 2 型糖尿病的慢性肾脏病：叙事性综述。
Cardiovasc Diabetol. 2023 Nov 16;22(1):316. doi: 10.1186/s12933-023-02023-y.
10
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.新型降糖药物对 2 型糖尿病患者心力衰竭风险的比较：网络荟萃分析。
JACC Heart Fail. 2018 Oct;6(10):823-830. doi: 10.1016/j.jchf.2018.05.021. Epub 2018 Sep 5.

引用本文的文献

1
Maintained sympathetic reactivity but blunted pressor response to static handgrip exercise in heart failure with preserved ejection fraction.射血分数保留的心力衰竭患者对静态握力运动保持交感神经反应性，但升压反应减弱。
Clin Auton Res. 2025 Feb 26. doi: 10.1007/s10286-025-01114-y.

本文引用的文献

1
Randomized Trial Comparing SGLT2 Inhibition and Hydrochlorothiazide on Sympathetic Traffic in Type 2 Diabetes.比较SGLT2抑制剂与氢氯噻嗪对2型糖尿病患者交感神经活动影响的随机试验
Kidney Int Rep. 2023 Sep 3;8(11):2254-2264. doi: 10.1016/j.ekir.2023.08.036. eCollection 2023 Nov.
2
Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?在射血分数保留的心力衰竭中对血流动力学假说提出质疑：运动能力是否受肺毛细血管楔压升高的限制？
Circulation. 2023 Jan 31;147(5):378-387. doi: 10.1161/CIRCULATIONAHA.122.061828. Epub 2022 Dec 16.
3
Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
HFpEF 治疗：GLP-1RA 联合 SGLT2-I 是否可改善糖尿病患者的心血管代谢风险和结局？
Int J Mol Sci. 2022 Nov 23;23(23):14598. doi: 10.3390/ijms232314598.
4
The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.血脑屏障与胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂的中枢效应之间的关系
Diabetes Metab Syndr Obes. 2022 Aug 22;15:2583-2597. doi: 10.2147/DMSO.S375559. eCollection 2022.
5
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1.
6
GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition.GLP1R 通过颈动脉体抑制来减轻高血糖引起的交感神经反应。
Circ Res. 2022 Mar 4;130(5):694-707. doi: 10.1161/CIRCRESAHA.121.319874. Epub 2022 Feb 1.
7
Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure.2 型糖尿病合并与不合并心力衰竭患者对达格列净的肌肉交感神经活动的不同反应。
J Am Heart Assoc. 2021 Nov 16;10(22):e022637. doi: 10.1161/JAHA.121.022637. Epub 2021 Oct 30.
8
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
9
An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is).胰高血糖素样肽-1受体激动剂（GLP-1RAs）与钠-葡萄糖协同转运蛋白-2抑制剂（SGLT-2is）在中枢神经系统代谢作用及效应方面的异同概述
Diabetes Metab Syndr Obes. 2021 Jun 29;14:2955-2972. doi: 10.2147/DMSO.S312527. eCollection 2021.
10
Neuroinflammation in heart failure: new insights for an old disease.心力衰竭中的神经炎症：旧病新见解。
J Physiol. 2020 Jan;598(1):33-59. doi: 10.1113/JP278864. Epub 2019 Dec 3.